@article{oai:nagasaki-u.repo.nii.ac.jp:00004744,
 author = {Wakata, Kouki and Tsuchiya, Tomoshi and Tomoshige, Koichi and Takagi, Katsunori and Yamasaki, Naoya and Matsumoto, Keitaro and Miyazaki, Takuro and Nanashima, Atsushi and Whitsett, Jeffrey A and Maeda, Yutaka and Nagayasu, Takeshi},
 issue = {7},
 journal = {BMJ Open},
 month = {Jul},
 note = {Objectives: To determine the use of the mucin proteins MUC5B and MUC5AC as prognosis markers for non-small cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) mutations. Setting: Patients who underwent surgical resection at Nagasaki University Hospital and related facilities in Japan between June 1996 and March 2013. Participant: 159 Japanese patients (male: n=103; female: n=56) with NSCLC, who underwent surgical resection (EGFR-mutant type: n=78, EGFR wild type: n=81). Results: Patients whose tumours expressed MUC5B had significantly longer overall survival and relapse-free survival compared to the MUC5B-negative patients with EGFR mutant NSCLC (p=0.0098 and p=0.0187, respectively). In patients with EGFR wild-type NSCLC, there was no association with MUC5B expression. MUC5AC expression was not different between EGFR mutant and wild-type NSCLC. Conclusions: Present findings indicate that MUC5B, but not MUC5AC, is a novel prognostic biomarker for patients with NSCLC carrying EGFR mutations but not for patients with NSCLC carrying wild-type EGFR., BMJ Open, 5(7), e008366; 2015},
 title = {A favourable prognostic marker for EGFR mutant non-small cell lung cancer: immunohistochemical analysis of MUC5B},
 volume = {5},
 year = {2015}
}